Now showing items 1-2 of 2
Tumor immune escape: Molecular mechanisms and counteracting strategies
Changes in HLA class I antigen and NK cell-activating ligand expression have been identified in malignant lesions. These changes are believed to play a major role in the clinical course of the disease since both HLA class ...
Cytotoxic T lymphocyte - tumor cell interaction: Monitoring HLA class I antigen and HLA class I antigen - tumor antigen derived peptide complex expression by malignant cells
Poor clinical response rates have been observed in the majority of the T cell-based immunotherapy clinical trials conducted to date. These disappointing results are likely to be caused, at least in part, by tumor cells' ...